InvestorsHub Logo
Followers 17
Posts 3780
Boards Moderated 0
Alias Born 02/21/2009

Re: None

Tuesday, 08/16/2016 8:54:00 AM

Tuesday, August 16, 2016 8:54:00 AM

Post# of 64388
Looks like NPHC hired someone with a lot of experience to get their drugs moving forward. very promising.

Dr. Vanderputten comes to us with over 30 years of management and clinical experience with governmental agencies as well as private sector biotech. As his first act as our CSO, he will spearhead our efforts to move our Multiple Sclerosis drug, RPI-78M, through the FDA approval process," he concluded.